Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
Autonomix Medical (NASDAQ: AMIX) has announced its participation in a Virtual Investor 'What This Means' segment scheduled for October 30, 2024. During this virtual event, Dr. Robert Schwartz, the company's Chief Medical Officer, will present additional findings from the 4-6 week follow-up data of the first five 'lead-in' patients from their ongoing proof-of-concept human clinical trial. The company, which specializes in precision nerve-targeted treatments, will make the segment accessible through their platform.
Autonomix Medical (NASDAQ: AMIX) ha annunciato la sua partecipazione a un segmento virtuale per investitori intitolato 'Cosa significa questo', previsto per 30 ottobre 2024. Durante questo evento virtuale, Dr. Robert Schwartz, il Chief Medical Officer dell'azienda, presenterà ulteriori risultati dei dati di follow-up dopo 4-6 settimane sui primi cinque pazienti 'lead-in' del loro attuale studio clinico di prova di concetto. L'azienda, specializzata in trattamenti precisi mirati ai nervi, renderà accessibile il segmento attraverso la propria piattaforma.
Autonomix Medical (NASDAQ: AMIX) ha anunciado su participación en un segmento virtual para inversores titulado 'Lo que esto significa', programado para el 30 de octubre de 2024. Durante este evento virtual, Dr. Robert Schwartz, el Director Médico de la empresa, presentará hallazgos adicionales de los datos de seguimiento a las 4-6 semanas de los primeros cinco pacientes 'lead-in' de su ensayo clínico en curso de prueba de concepto. La empresa, que se especializa en tratamientos precisos dirigidos a los nervios, hará que el segmento sea accesible a través de su plataforma.
Autonomix Medical (NASDAQ: AMIX)는 2024년 10월 30일로 예정된 가상 투자자 '이 무엇을 의미합니까' 세그먼트에 참여한다고 발표했습니다. 이 가상 행사에서 Dr. Robert Schwartz는 현재 진행 중인 개념 증명 인간 임상 시험의 첫 다섯 명 '리드 인' 환자의 4-6주 후속 데이터에 대한 추가 결과를 발표할 것입니다. 신경 표적 정밀 치료를 전문으로 하는 이 회사는 해당 세그먼트를 자사 플랫폼을 통해 접근 가능하게 할 것입니다.
Autonomix Medical (NASDAQ: AMIX) a annoncé sa participation à un segment d'investisseurs virtuel intitulé 'Ce que cela signifie', prévu pour le 30 octobre 2024. Au cours de cet événement virtuel, Dr. Robert Schwartz, le directeur médical de l'entreprise, présentera des résultats supplémentaires des données de suivi à 4-6 semaines des cinq premiers patients 'lead-in' de leur essai clinique de preuve de concept en cours. L'entreprise, spécialisée dans des traitements ciblés avec précision sur les nerfs, rendra le segment accessible via sa plateforme.
Autonomix Medical (NASDAQ: AMIX) hat die Teilnahme an einem virtuellen Investorensegment mit dem Titel 'Was das bedeutet' angekündigt, das für den 30. Oktober 2024 geplant ist. Während dieser virtuellen Veranstaltung wird Dr. Robert Schwartz, der Chief Medical Officer des Unternehmens, zusätzliche Erkenntnisse aus den 4-6 Wochen Follow-up-Daten der ersten fünf 'Lead-in'-Patienten aus ihrer laufenden Proof-of-Concept-Studie präsentieren. Das Unternehmen, das auf präzise nervenzielgerichtete Behandlungen spezialisiert ist, wird das Segment über seine Plattform zugänglich machen.
- None.
- None.
THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will release a Virtual Investor “What This Means” segment on Wednesday, October 30, 2024.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix will discuss additional findings from the 4-6 week follow-up data from the first five “lead-in” patients in the Company’s ongoing proof-of-concept (PoC) human clinical trial.
The Virtual Investor “What This Means” segment will be accessible here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
FAQ
When will Autonomix Medical (AMIX) present their clinical trial follow-up data?
What will be discussed in Autonomix Medical's (AMIX) October 30 virtual presentation?
How many patients' data will be covered in Autonomix Medical's (AMIX) October 2024 presentation?
Who will present Autonomix Medical's (AMIX) clinical trial findings on October 30, 2024?
